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Abstract 
Background: Blood pressure (BP) measurement is increasingly carried out through home or 
ambulatory monitoring, yet existing cardiovascular risk scores were developed for use with 
measurements obtained in clinic. 
Aim: To describe differences in cardiovascular risk estimates obtained using ambulatory or home BP 
measurements instead of clinic readings.  
Design and setting: Secondary analysis of data from adults aged 30-84 without prior history of 
cardiovascular disease (CVD) in two BP monitoring studies (BP-Eth and HOMERUS). 
Method: The primary comparison was Framingham risk calculated using BP measured as in the 
Framingham study or daytime ambulatory BP measurements. The QRISK2 and SCORE risk equations 
were also studied. Statistical and clinical significance were determined using the Wilcoxon signed-
rank test and scatter plots respectively. 
Results: In 442 BP-Eth patients (mean age = 58 years, 50% female) the median absolute difference in 
10-year Framingham cardiovascular risk calculated using BP measured as in the Framingham study 
or daytime ambulatory BP measurements was 1.84% (interquartile range 0.65 to 3.63, p=0.67). Only 
31/ 442 (7.0%) of patients were reclassified across the 10% risk treatment threshold. In 165 
HOMERUS patients (mean age = 56 years, 46% female) the median difference in 10-year risk was 
2.76% (IQR 1.19 to 6.39, p<0.001) and only 8/165 (4.8%) of patient were reclassified. 
Conclusion: Estimates of cardiovascular risk are similar when calculated using BP measurements 
obtained as in the risk score derivation study or through ambulatory monitoring. Further research is 
required to determine if differences in estimated risk would meaningfully influence risk score 
accuracy. 
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How this fits in: Out-of-office blood pressure (BP) measurement is increasingly common but 
cardiovascular risk scores were developed using clinic BP measurements. It is unclear how estimates 
of cardiovascular risk may be affected by the use of out-of-office measurements in risk prediction 
algorithms. We have shown that differences in risk are generally small and few patients are 
reclassified across treatment thresholds when using different BP measurements.  Extra care on the 
part of clinicians may be warranted in subgroups with large BP differences or those with risk 
estimates close to risk thresholds. 
  
Introduction 
Current UK and international guidance recommends that high blood pressure (hypertension) is 
diagnosed through 24-hour ambulatory blood pressure monitoring (ABPM), or week long home 
monitoring.(1–5) Furthermore, many patients with hypertension also monitor their blood pressure 
(BP) at home.(6) Consequently, BP measurements obtained in several settings, may be used to 
manage hypertension and estimate cardiovascular risk.(7,8) 
Risk assessments are recommended in order to treat those at highest risk of cardiovascular disease 
(CVD). The majority of published cardiovascular risk scores, including the Framingham,(9) QRISK2(10) 
and SCORE(11) equations, were developed using BP measurements obtained in a clinic setting and, 
ideally, should be used with measurements obtained similarly. Despite this reflecting the original 
derivation of the scores, use of clinic BP may systematically over- or underestimate risk in patients 
with large discrepancies between clinic and out-of-office BP (white coat(12,13) or masked 
effects(14)). This is because home and ambulatory BP measurements are stronger predictors of CVD 
than clinic readings.(15–17) 
Although masked and white coat hypertension may only affect a minority of the population,(18,19) 
the extent to which this problem affects risk estimates and subsequent clinical decisions has been 
little studied. One previous study examined a related problem of end digit preference in clinic BP 
readings in the Framingham risk score,(20) but was limited to a single risk score and used simulated 
data. Hence, this study aimed to describe differences in estimated cardiovascular risk when using 
out-of-office instead of clinic BP measurements and to determine how clinical decisions might be 
affected by these differences. We used data from the Blood Pressure in different Ethnic groups (BP-
Eth) study(21) and the Home versus Office blood pressure MEasurements: Reduction of Unnecessary 
treatment Study (HOMERUS).(22) 
 
Methods 
Study population 
The BP-Eth cohort has been described in full previously.(21,23) Briefly, this cross-sectional study 
compared clinic, home and ambulatory BP in UK patients aged 40 to 74, with or without 
hypertension, who were white British, white Irish, South Asian or African-Caribbean. For this 
analysis, patients with a prior history of cardiovascular disease were excluded. Clinic measurement 
used the BpTRU sphygmomanometer.(24) Measurements on both arms were taken at the first visit 
and on the higher reading arm at subsequent visits. ABPM (Spacelabs 90217)(25) used half hourly 
measurement from 0800 to 2300 and hourly measurement overnight. Home BP measurements were 
obtained twice in the morning and evening over seven days. 
HOMERUS was a randomized trial in patients with essential hypertension aged 18 and over from the 
Netherlands. Patients with history of cardiovascular disease or other severe disease were excluded. 
Patients were randomized into an office or home monitoring group with antihypertensive treatment 
adjusted accordingly. Three office BP measurements were taken in the non-dominant arm at each 
visit using an automated oscillometric device (Omron 705, Japan).(26) Home BP measurements 
(three in the morning and evening over seven days) were made with the same monitor before each 
study visit. ABPM was carried out at the beginning and end of the study (following treatment 
washout and at optimal titration respectively) with readings every 15 minutes from 0700 to 2300 
and every 30 minutes overnight. For this analysis, patients aged 25 to 84 years old from the 
intervention arm only were included, due to the age restrictions of the QRISK2 risk equation. 
Statistical analysis 
We estimated cardiovascular risk using the Framingham, QRISK2 and SCORE risk equations, (9–11) 
which are =commonly used in UK general practice.(27) We compared risk estimates calculated using 
systolic BP values obtained using different measurement techniques in the clinic, at home or through 
ABPM (Box 1). The primary comparison was risk calculated using BP measured as in the derivation 
study of each risk score with risk calculated using daytime ambulatory BP (due to its recommended 
use in diagnosis of hypertension).(1) We calculated Framingham risk in primary analyses as BP 
measurement in the Framingham study was consistent across patients and well documented.(28) 
Comparatively, BP measurement in the QRISK2 and SCORE derivation studies varied across 
patients.(10,11) 
Absolute differences in risk were summarized by medians/ interquartile ranges and were compared 
using the non-parametric Wilcoxon signed-rank test. Clinical significance was determined by 
calculating the proportion of people reclassified above or below the threshold for statin treatment 
(10% for all CVD and 5% for CVD mortality) and scatter plots. Analyses were carried out in the BP-Eth 
and HOMERUS cohorts separately, using Stata 14.2.(29) 
Missing data 
Analysis was restricted to patients who had complete covariate data and at least three BP readings 
at visit one in BP-Eth (when measurements were taken in both arms) and visit ten in HOMERUS 
(when concurrent ABPM and cholesterol measurement occurred). Twelve home BP readings 
measured on at least three days, and 19 ABPM readings (14 daytime and five night-time) was 
required.(1,30) Cholesterol data was not collected in BP-Eth, so was simulated from a normal 
distribution using means and standard deviations in each age-sex strata from the Health Survey for 
England 2011.(31) Townsend deprivation data (a UK measure of material deprivation based on 
employment, car ownership, home ownership and household overcrowding) was not available in 
HOMERUS(32) and hence patients in HOMERUS were assigned non-risk modifying values of 
deprivation. 
 
Results 
A total of 442 patients from the BP-Eth cohort and 165 patients from the HOMERUS cohort were 
included (Table 1). Patients in the BP-Eth cohort were older and were from a mix of ethnic 
backgrounds by design. HOMERUS patients were less likely to have risk factors for cardiovascular 
disease, but had higher clinic BP values. Average differences in BP measurements were small, but 
there were large differences for some individuals, especially in the HOMERUS cohort (Supplement, 
Figures S1 and S2). 
Differences in Framingham risk using ambulatory, home or clinic BP measurements 
In the BP-Eth cohort, comparing estimates of Framingham risk calculated using BP taken to be the 
mean of 2nd and 3rd measurements on the left arm or an alternative measure revealed that observed 
risk differences were generally small. Median absolute differences were less than 2% for all 
comparisons except night-time ambulatory BP measurement (Table 2). There were no significant 
differences in Framingham risk when calculated using daytime ambulatory BP (p=0.67), home BP 
excluding the first days readings (p=0.08), or BP measured according to current guidance (p=0.26). 
Figure 1 shows the number of BP-Eth patients reclassified across the 10% 10-year risk threshold 
when Framingham risk was calculated using daytime ambulatory BP compared to the mean of 2nd 
and 3rd clinic measurements on the left arm. In total 31/ 442 (7.0%) of patients were reclassified 
and those reclassified had risk estimates close to the threshold. Patients were reclassified upwards/ 
downwards if their ambulatory BP was higher / lower than their clinic BP respectively, reflecting the 
increased risk associated with higher BP. The largest differences in risk were observed for those 
already at high risk (Figure S3A) but this pattern was not apparent when considering risk on the log-
scale (Figure S3B). Similar patterns were seen when calculating risk using home or guideline 
recommended clinic BP (Figures S4 and S5). 
In the HOMERUS cohort, compared to the BP-Eth cohort, larger median differences in risk were 
observed when using home or ambulatory BP in the Framingham risk score (Table 3). Differences 
were statistically significant when using BP measured through daytime ABPM (p<0.001), home 
monitoring excluding the first days readings (p<0.001), or according to current guidance (p=0.006). 
As in the BP-Eth cohort, small numbers of people were reclassified across the 10% 10-year risk 
threshold when calculating risk with daytime ambulatory BP (4.8% reclassified, Figure 2), although 
estimated risk was lower in the majority of patients. Similar patterns were observed when 
calculating risk using home or guideline recommended clinic BP (Figures S6 and S7). 
Differences in QRISK2 risk using ambulatory, home or clinic BP measurements 
Median absolute differences in estimated QRISK2 risk were less than 1.5% in the BP-Eth cohort when 
using any alternative measures of BP (compared to a single clinic measure) and interquartile ranges 
were narrower than observed for Framingham risk (Table S1). This suggests that the contribution of 
BP to overall risk is lower in the QRISK2 equation compared to the Framingham equation. Although 
differences in risk were statistically significant when using BP measured through ambulatory 
monitoring (p<0.001), home monitoring excluding the first day (p<0.001) or as in current guidance 
(p<0.001), fewer people were reclassified across the 10-year risk threshold compared to those 
observed when using the Framingham equation (Figures S8-S10). Similar results were observed in 
the HOMERUS cohort, with the majority of patients having lower estimated risk when using 
ambulatory BP (Table S2, Figures S11-S13). 
Differences in SCORE risk using ambulatory, home or clinic BP measurements 
Finally, differences in SCORE risk estimates f were also small (below 0.5%, Table S3). Differences 
across risk scores were not directly comparable, since the SCORE equation estimates risk of CVD 
death and absolute risk levels are lower. Differences in risk were statistically significant when 
calculated using BP measured through ambulatory or home monitoring, or according to current 
guidance (p<0.001 in all cases). Less than 10% of patients were reclassified above/ below the 5% 10-
year CVD mortality risk threshold (Figures S14-S16). The relative variation in risk observed was 
comparable to/   more than that observed for the Framingham/ QRISK2 equation respectively, 
reinforcing the suggestion that BP contributes less to the risk estimate in the QRISK2 equation. In the 
HOMERUS cohort, use of ambulatory BP primarily resulted in a reduction in estimated risk. No 
patients were reclassified upwards but 26/165 (15.8%) patients were reclassified from high to low 
risk (Table S3, Figure S17-S19). 
 
Discussion 
This analysis has shown that using BP measurements obtained through ambulatory or home instead 
of clinic monitoring may have little effect on CVD risk estimates obtained from the Framingham, 
QRISK2 or SCORE risk equations. Where differences did occur, fewer than 1 in 5 people were 
reclassified across risk thresholds for treatment and those reclassified tended to have risk estimates 
close to the thresholds. The relative contribution of BP to risk appeared to be lower in QRISK2 
compared to the Framingham or SCORE equation.  
Strengths and limitations 
The results of this study have been demonstrated in two populations from distinct countries with 
differing cardiovascular risk profiles and therefore have good face validity. Findings can be 
considered generalizable to other populations due to the different ethnic composition of the two 
studies. Results were also similar across the three risk scores studied. 
A limitation of this analysis was that outcomes data were not available to allow comparison between 
estimated and observed risks. Hence, we could not determine whether using one type of BP 
measurement over another results in more accurate risk assessment. However, since most patients 
remained at high or low risk, the ability of risk equations to detect those at high risk (discrimination) 
is likely to be similar regardless of the type of BP measurement used. Calibration (agreement 
between predicted and observed risk) may well differ and this requires further assessment in formal 
validation studies. 
Data for cholesterol had to be simulated in the BP-Eth dataset, Townsend deprivation scores were 
fixed at non-risk modifying values in the HOMERUS dataset, and only complete case analyses were 
carried out. As such, we have described possible changes in risk estimates across a range of risk 
values and BP differences. Further work would be required to estimate risk differences at the 
population level.  
Clinic BP measurements in both cohorts were obtained using automated devices, which likely limited 
the presence of white-coat effects compared to routine practice.(33) We attempted to mimic 
routine clinic measurement as far as possible by studying recommended protocols (which have been 
shown to be followed in a majority of cases in UK primary care)(34) and single BP readings. Larger 
differences in estimated risk may be observed routinely. 
Comparisons with the literature 
Previous research carried out in New Zealand examined differences in Framingham risk estimates 
when BP measurements were subject to zero-end digit preference. The study found that the mean 
difference in risk was 0.16% and that 2.4% of individuals were reclassified across the 20% risk 
threshold.(20) This study is a generalisation of the same problem: that of using BP measurements 
with differing levels of bias/ measurement error from those used in risk score derivation and our 
results support the previous findings.  
The results of this analysis are also in line with the previous work of several authors, aiming to 
modify CVD risk scores for use with home instead of clinic BP measurements.(35) Modifications to 
existing equations were modest and differences in risk between the modified equations and existing 
risk equations were small. Our results indicate that any changes to risk scores for use with 
ambulatory measurements would be similarly modest. 
Although home and ambulatory BP is predictive of CVD risk over and above clinic BP,(15,16) adding 
daytime ambulatory BP measurements to the Framingham risk score in a cohort of older men did 
not improve its accuracy.(36) This suggests that the type of BP measurements included in risk scores 
may have little influence on accuracy. The small differences in risk observed in this study again 
support these previous findings.  
Implications for research and practice 
Broadly, our results indicate that healthcare professionals may not need to be unduly worried about 
which BP measurements to use when calculating cardiovascular risk and the choice of risk score may 
be of greater importance. However, there were differences in results between the HOMERUS cohort 
(a population selected based on high clinic BP) and BP-Eth (a mixed population of normotensive and 
hypertensive patients). This suggests that greater care may be warranted in those known or likely to 
have large white-coat/ masked effects and in those with estimated risk close to treatment 
thresholds, as this combination of characteristics is most likely to lead to reclassification below/ 
above treatment thresholds respectively. 
Although average risk differences were small, up to 1 in 6 people were reclassified in some analyses. 
If such results are borne out in wider scale analyses, this could have potentially important 
implications when extrapolated to the population level. However, a recent UK-based study showed 
that a minority of patients identified at high risk of CVD between 2010 and 2013 were initiated on 
treatment,(37) indicating that such clinical decisions are influenced by several factors. 
The apparent lower contribution of BP to risk in QRISK2 should be further explored. QRISK2 includes 
more risk factors than Framingham or SCORE, including a term for treated hypertension that may 
capture part of the BP effect. This is consistent with the relatively smaller hazard ratio for BP in 
QRISK2 (1.20 per 20 mm Hg for CVD events),(10) compared to hazard ratios of at least 1.49 for CHD 
and stroke mortality from observational studies,(38) and 1.60 for in primary prevention groups from 
BP lowering trials.(39)  
In conclusion, we have shown that differences in cardiovascular risk estimates, when calculated 
using BP measurements obtained in a clinical research setting different to that of the risk score 
derivation studies, are likely to be small in most cases.  Further research is required to determine 
whether meaningful clinically important differences occur in subgroups and at the population level 
in daily practice. 
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Box 1: Summary of different blood pressure measurement techniques considered for comparison 
1. Clinic blood pressure* 
a. As defined in the derivation studies of each risk score 
i. Framingham: mean of the 2nd and 3rd clinic measurements in the left arm 
ii. QRISK2: first clinic measurement in a randomly selected arm 
iii. SCORE: first clinic measurement in a randomly selected arm 
b. Defined according to current UK guidance. This was defined as the first measurement if 
less than 140/90mm Hg. If ≥140/90 mm Hg, then the second measurement was 
considered. If the second measurement differed from the first by >5 mm Hg systolic 
then the third measurement was also considered. The minimum of the last two 
measurements was used in analyses. BP readings were taken from the higher reading 
arm in patients who had a difference between arms of ≥20 mm Hg systolic, which was 
sustained after two readings, or otherwise in a random arm. 
2. Home blood pressure 
a. Mean of two readings in the morning and two readings in the evening over seven days, 
excluding the first day’s readings. 
b. As in 2a, including the first day’s readings. 
3. Ambulatory blood pressure 
a. Daytime ambulatory BP providing at least 14 valid measurements were available. 
b. Night-time ambulatory BP providing at least five valid measurements were available. 
c. 24-hour ambulatory BP providing at least 19 valid measurements were available. 
* Clinic BP was measured in the non-dominant arm in HOMERUS. Where measurement techniques specify a 
measurement arm, this was implemented in BP-Eth as specified. In HOMERUS this was implemented using the 
available measurements, disregarding measurement arm. 
 
 
Table 1: Characteristics of the BP-Eth (N=442) and HOMERUS cohorts (N=165) 
 BP-Eth cohort 
(N=442) 
HOMERUS cohort 
(N=165) Variable Mean (SD)/ N (% Mean (SD)/ N (%
Age (years) 58.4 (9.4) 55.6 (9.7) 
Female 222 (50.2) 75 (45.5) 
BMI (kg/m2) 29.1 (4.5) 27.5 (4.2) 
Current smoker 66 (14.9) 30 (18.2) 
Chronic kidney disease 3 (6.8) 0 (0.0) 
Atrial fibrillation 16 (3.6) 0 (0.0) 
Treated hypertension 249 (56.3) 165 (100.0) 
Left ventricular hypertrophy 0 (0.0) 0 (0.0) 
Type 1 diabetes 2 (0.5) 6 (3.6) 
Type 2 diabetes 57 (12.9) 37 (22.4) 
Townsend score 6.1 (4.1) 0.1 (0.06) 
Total cholesterol (mmol/L) (simulated) 5.4 (1.1) 5.5 (1.1) 
HDL cholesterol (mmol/L) (simulated) 1.5 (0.4) 1.4 (0.4) 
Total/HDL cholesterol (mmol/L) 4.0 (1.7) 4.4 (1.4) 
Ethnicity: White 203 (45.9) 165 (100.0) 
Ethnicity: Indian 79 (17.9) 0 (0.0) 
Ethnicity: Pakistani 24 (5.4) 0 (0.0) 
Ethnicity: Bangladeshi 5 (1.1) 0 (0.0) 
Ethnicity: Black Caribbean 115 (26.0) 0 (0.0) 
Ethnicity: Black African 16 (3.6) 0 (0.0) 
Systolic BP (mm Hg): single reading (random arm) 136.2 (18.3) 146.5 (19.1) 
Systolic BP (mm Hg): mean of 2nd and 3rd readings in left arm 132.4 (17.1) 142.3 (17.1) 
Systolic BP (mm Hg): according to current guidance 132.8(15.9) 141.4 (16.2) 
Systolic BP (mm Hg): mean of home readings excluding the 
first day 
133.4 (12.4) 134.0 (10.5) 
Systolic BP (mm Hg): mean of daytime ambulatory readings 133.0(14.2) 131.3 (9.9) 
QRISK2 10-year CVD risk 16.0 (12.1) 13.2 (8.8) 
Framingham 10-year CVD risk 15.6 (10.8) 19.6 (13.5) 
SCORE 10-year CVD death risk 3.1 (3.3) 3.3 (3.7) 
 
  
Table 2: Differences in Framingham risk estimates using alternative summary measures of mean 
blood pressure in the BP-Eth cohort 
Alternative BP measurement 
used in risk score 
Median absolute 
difference (%) 
Inter-quartile 
range 
Difference range 
(original – 
alternative) 
Ambulatory measurements 
Daytime ABPM 1.84 0.65 3.63 -18.04 12.59 
Night-time ABPM 2.65 1.09 5.91 -17.96 19.61 
24-hour ABPM 1.85 0.76 3.63 -17.61 13.45 
Home measurements 
Excluding first days readings 1.66 0.61 3.12 -15.94 11.56 
Including first days readings 1.69 0.58 3.09 -16.54 12.23 
Clinic measurements 
Current guidance 0.78 0.35 1.62 -15.22 9.15 
 
 
 
 
  
Table 3: Differences in Framingham risk estimates using alternative summary measures of mean 
blood pressure in the HOMERUS cohort 
Alternative BP measurement 
used in risk score 
Median absolute 
difference (%) 
Inter-quartile 
range 
Difference range 
(original – 
alternative) 
Ambulatory measurements 
Daytime ABPM 2.76 1.19 6.39 -8.65 18.80 
Night-time ABPM 5.35 2.04 11.42 -5.88 28.28 
24-hour ABPM 3.05 1.10 7.40 -7.97 20.93 
Home measurements 
Excluding first days readings 2.50 0.89 5.32 -8.52 16.33 
Including first days readings 2.41 0.92 5.24 -9.03 16.05 
Clinic measurements 
Current guidance 0.51 0.21 1.32 -3.56 4.34 
 
 
  
Figure 1: Framingham risk estimates in the BP-Eth cohort calculated using BP measurements 
obtained as in the Framingham study or through daytime ABPM 
Figure 2: Framingham risk estimates in the HOMERUS cohort calculated using BP measurements 
obtained as in the Framingham study or through daytime ABPM 
 
 
